title: Slow recovery of follicular B cells and marginal zone B cells after chemotherapy: implications for humoral immunity.
abstract: Although most chemotherapeutic agents are known to cause primarily reduction or suppression of immune responses, surprisingly little is known about the influence of cytostatic agents on lymphoid tissue compartments such as the splenic marginal zone. The marginal zone plays an important role in the defence against encapsulated bacteria, which are potential candidates for postchemotherapeutic infections. We studied the effect of three different cytostatic agents (cisplatin, methotrexate, and cyclophosphamide) on B cell subpopulations in a rat model. Rats received a single dose of a single cytostatic agent and were sacrificed at different time points after treatment. Bone marrow, blood, mesenteric lymph nodes and spleens were analysed by flow-cytometry and immunohistochemistry. All three cytostatic agents showed severe bone marrow depression. CP and MTX showed only mild reduction of cell populations in the spleen. CyPh showed a severe reduction of recirculating follicular B (RF-B) cells and marginal zone B (MZ-B) cells. At day 24 most populations were already recovered, but RF-B cells and MZ-B cells were still reduced. The reduction of the marginal zone and late recovery may imply that, beside the overall increased infection risk due to neutropenia, patients treated with chemotherapy are at risk for developing infections from encapsulated bacteria for a considerable period of time after treatment, extending beyond the period of bone marrow depression.
authors: Department of Pathology, University and University Hospital Groningen, PO Box 30.001, NL-9700 RB, Groningen, The Netherlands.
authors: A
authors: A
authors: Zandvoort
authors: M E
authors: ME
authors: Lodewijk
authors: P A
authors: PA
authors: Klok
authors: P M
authors: PM
authors: Dammers
authors: F G
authors: FG
authors: Kroese
authors: W
authors: W
authors: Timens
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D000970:Antineoplastic Agents / Q000633:toxicity*; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects*; D001773:Blood Cells / Q000166:cytology / Q000187:drug effects; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects*; D002945:Cisplatin / Q000633:toxicity; D003520:Cyclophosphamide / Q000633:toxicity; D008198:Lymph Nodes / Q000166:cytology / Q000187:drug effects; D008297:Male; D008643:Mesentery / Q000166:cytology / Q000187:drug effects; D008727:Methotrexate / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000166:cytology / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D002945:Cisplatin; D008727:Methotrexate